Literature DB >> 20068550

BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver.

Ekaterina Breous1, Suryanarayan Somanathan, James M Wilson.   

Abstract

Following adeno-associated virus (AAV) gene transfer to the liver, both C57BL/6 and BALB/c mice show long-term expression of nonself transgene antigens along with the absence of a transgene-specific immune response. However, in this study, we report that despite the equal ability to induce T-cell tolerance to vector-encoded antigens, the underlying mechanisms are entirely different in these two strains. We have previously shown that in C57BL/6 mice, cytotoxic T lymphocyte (CTL) responses to systemic AAV-delivered antigens are suppressed by combined actions of hepatic regulatory T cells (Tregs), Kupffer cells, and hepatic suppressive cytokines. In stark contrast, our present findings reveal that such tolerogenic response is not induced in the liver of BALB/c mice systemically administered with AAV. As a result, these mice fail to suppress a transgene-specific CTL response induced by a strong immunogenic challenge and express dramatically reduced levels of AAV-encoded antigen. Interestingly, there was active B-cell tolerance to the transgene antigen, which was mediated by splenic Tregs. We conclude that lack of tolerance induction in the liver renders BALB/c mice susceptible to CTL-mediated clearance of transduced hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20068550      PMCID: PMC2862531          DOI: 10.1038/mt.2009.301

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  38 in total

1.  In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.

Authors:  I Hoerr; R Obst; H G Rammensee; G Jung
Journal:  Eur J Immunol       Date:  2000-01       Impact factor: 5.532

2.  Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.

Authors:  Y Ge; S Powell; M Van Roey; J G McArthur
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

3.  Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.

Authors:  P A Fields; E Armstrong; J N Hagstrom; V R Arruda; M L Murphy; J P Farrell; K A High; R W Herzog
Journal:  Gene Ther       Date:  2001-03       Impact factor: 5.250

4.  Local intrahepatic CD8+ T cell activation by a non-self-antigen results in full functional differentiation.

Authors:  Sherry A Wuensch; Robert H Pierce; I Nicholas Crispe
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

5.  Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.

Authors:  Ou Cao; Eric Dobrzynski; Lixin Wang; Sushrusha Nayak; Bethany Mingle; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2007-04-16       Impact factor: 22.113

6.  Muscle as a target for supplementary factor IX gene transfer.

Authors:  Brad E Hoffman; Eric Dobrzynski; Lixin Wang; Lauren Hirao; Federico Mingozzi; Ou Cao; Roland W Herzog
Journal:  Hum Gene Ther       Date:  2007-07       Impact factor: 5.695

Review 7.  The immunology of susceptibility and resistance to Leishmania major in mice.

Authors:  David Sacks; Nancy Noben-Trauth
Journal:  Nat Rev Immunol       Date:  2002-11       Impact factor: 53.106

8.  Sustained expression of human apo A-I following adenoviral gene transfer in mice.

Authors:  B De Geest; S Van Linthout; D Collen
Journal:  Gene Ther       Date:  2001-01       Impact factor: 5.250

9.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

10.  Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins.

Authors:  Alberto Auricchio; Erin O'Connor; Daniel Weiner; Guang-Ping Gao; Markus Hildinger; Lili Wang; Roberto Calcedo; James M Wilson
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

View more
  18 in total

1.  Hepatic AAV gene transfer and the immune system: friends or foes?

Authors:  Roland W Herzog
Journal:  Mol Ther       Date:  2010-06       Impact factor: 11.454

2.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.

Authors:  Steven J Gray; Valerie Matagne; Lavanya Bachaboina; Swati Yadav; Sergio R Ojeda; R Jude Samulski
Journal:  Mol Ther       Date:  2011-04-12       Impact factor: 11.454

Review 3.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

Review 4.  Liver induced transgene tolerance with AAV vectors.

Authors:  Geoffrey D Keeler; David M Markusic; Brad E Hoffman
Journal:  Cell Immunol       Date:  2017-12-05       Impact factor: 4.868

5.  Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.

Authors:  Kleopatra Rapti; Vedell Louis-Jeune; Erik Kohlbrenner; Kiyotake Ishikawa; Dennis Ladage; Sergei Zolotukhin; Roger J Hajjar; Thomas Weber
Journal:  Mol Ther       Date:  2011-09-13       Impact factor: 11.454

6.  Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity.

Authors:  Laurent Bartolo; Stéphanie Li Chung Tong; Pascal Chappert; Dominique Urbain; Fanny Collaud; Pasqualina Colella; Isabelle Richard; Giuseppe Ronzitti; Jocelyne Demengeot; David A Gross; Federico Mingozzi; Jean Davoust
Journal:  JCI Insight       Date:  2019-06-06

Review 7.  The complex and evolving story of T cell activation to AAV vector-encoded transgene products.

Authors:  Lauren E Mays; James M Wilson
Journal:  Mol Ther       Date:  2010-11-30       Impact factor: 11.454

8.  Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer.

Authors:  Brad E Hoffman; Ashley T Martino; Brandon K Sack; Ou Cao; Gongxian Liao; Cox Terhorst; Roland W Herzog
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

9.  Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.

Authors:  Dwaipayan Sen; Rupali A Gadkari; Govindarajan Sudha; Nishanth Gabriel; Yesupatham Sathish Kumar; Ruchita Selot; Rekha Samuel; Sumathi Rajalingam; V Ramya; Sukesh C Nair; Narayanaswamy Srinivasan; Alok Srivastava; Giridhara R Jayandharan
Journal:  Hum Gene Ther Methods       Date:  2013-04       Impact factor: 2.396

Review 10.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.